Vaxcyte, Inc. PCVX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s accrued expenses?
- Vaxcyte, Inc. (PCVX) reported accrued expenses of $7.99M in Q1 2026.
- How has Vaxcyte, Inc.'s accrued expenses changed year-over-year?
- Vaxcyte, Inc.'s accrued expenses increased by 33.3% year-over-year, from $5.99M to $7.99M.
- What is the long-term trend for Vaxcyte, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s accrued expenses has grown at a 140.8% compound annual growth rate (CAGR), from $284K to $23M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.